XML 39 R25.htm IDEA: XBRL DOCUMENT
v3.20.4

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS |
Schedule of amortized cost and estimated fair values for available-for-sale securities | Available-for-sale securities are summarized below: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, 2020
​ | ​ | ​ | ​ | ​ | Gross | ​ | Gross | ​ | ​ | ​
​ | ​ | ​ | ​ | Unrealized | ​ | Unrealized | ​ | Estimated
(In thousands) |  | Amortized Cost |  | Gains |  | Losses |  | Fair Value
Money market funds (1) | ​ | $ | 204,808 | ​ | $ | — | ​ | $ | — | ​ | $ | 204,808
Total | ​ | $ | 204,808 | ​ | $ | — | ​ | $ | — | ​ | $ | 204,808
(1) | Money market funds were included in cash and cash equivalents on the consolidated balance sheets.
​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, 2019
​ | ​ | ​ | ​ | ​ | Gross | ​ | Gross | ​ | ​ | ​
​ | ​ | ​ | ​ | Unrealized | ​ | Unrealized | ​ | Estimated
(In thousands) |  | Amortized Cost |  | Gains |  | Losses |  | Fair Value
U.S. government securities (1) | ​ | $ | 53,799 | ​ | $ | 35 | ​ | $ | — | ​ | $ | 53,834
U.S. commercial paper (1) | ​ |  | 18,915 | ​ |  | — | ​ |  | — | ​ |  | 18,915
Money market funds (2) | ​ |  | 233,992 | ​ |  | — | ​ |  | — | ​ |  | 233,992
Total | ​ | $ | 306,706 | ​ | $ | 35 | ​ | $ | — | ​ | $ | 306,741
(1) | U.S. government securities and U.S. commercial paper were included in short-term marketable securities on the consolidated balance sheets.
(2) | Money market funds were presented in cash and cash equivalents on the consolidated balance sheets.
Schedule of available-for-sale securities measured at fair value on a recurring basis | The estimated fair values were as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Estimated Fair Value Measurements as of December 31, 2020 Using:
​ | ​ | Quoted Price | ​ | Significant | ​ | ​ | ​ | ​ | ​
​ | ​ | in Active | ​ | Other | ​ | Significant | ​ | ​ | ​
​ | ​ | Markets for | ​ | Observable | ​ | Unobservable | ​ | ​ | ​
Types of Instruments | ​ | Identical Assets | ​ | Inputs | ​ | Inputs | ​ | ​ | ​
(In thousands) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total
Assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Money market funds | ​ | $ | 204,808 | ​ | $ | — | ​ | $ | — | ​ | $ | 204,808
Investments held by ISP Fund LP (1) | ​ | ​ | 299,288 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 299,288
Equity investment - Armata Common Stock | ​ | ​ | 25,958 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 25,958
Equity investment - Armata Warrants | ​ | ​ | — | ​ | ​ | 18,049 | ​ | ​ | — | ​ | ​ | 18,049
Equity investment - Entasis Common Stock | ​ | ​ | 46,122 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 46,122
Equity investment - Entasis Warrants | ​ | ​ | — | ​ | ​ | 31,882 | ​ | ​ | — | ​ | ​ | 31,882
Equity investment - InCarda Warrants | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,147 | ​ | ​ | 1,147
Total assets measured at estimated fair value | ​ | $ | 576,176 | ​ | $ | 49,931 | ​ | $ | 1,147 | ​ | $ | 627,254
Debt | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2023 Notes | ​ | $ | — | ​ | $ | 239,779 | ​ | $ | — | ​ | $ | 239,779
2025 Notes | ​ | ​ | — | ​ | ​ | 206,135 | ​ | ​ | — | ​ | ​ | 206,135
Total fair value of debt | ​ | $ | — | ​ | $ | 445,914 | ​ | $ | — | ​ | $ | 445,914
(1) | The investments, which consisted of equity investments of $14.5 million and money market funds of $284.8 million, held by ISP Fund LP were subject to a 36-month lock-up period from our initial contribution date, December 11, 2020.
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Estimated Fair Value Measurements as of December 31, 2019 Using:
​ | ​ | Quoted Price | ​ | Significant | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | in Active | ​ | Other | ​ | Significant | ​ | ​ | ​
​ | ​ | Markets for | ​ | Observable | ​ | Unobservable | ​ | ​ | ​
Types of Instruments | ​ | Identical Assets | ​ | Inputs | ​ | Inputs | ​ | ​ | ​
(In thousands) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total
Assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. government securities | ​ | $ | — | ​ | $ | 53,834 | ​ | $ | — | ​ | $ | 53,834
U.S. commercial paper | ​ | ​ | — | ​ |  | 18,915 | ​ |  | — | ​ |  | 18,915
Money market funds | ​ | ​ | 233,992 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 233,992
Total assets measured at estimated fair value | ​ | $ | 233,992 | ​ | $ | 72,749 | ​ | $ | — | ​ | $ | 306,741
Debt | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2023 Notes | ​ | $ | — | ​ | $ | 243,394 | ​ | $ | — | ​ | $ | 243,394
2025 Notes | ​ | ​ | — | ​ | ​ | 208,976 | ​ | ​ | — | ​ | ​ | 208,976
Total fair value of debt | ​ | $ | — | ​ | $ | 452,370 | ​ | $ | — | ​ | $ | 452,370
Armata |
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS |
Schedule of balance sheets and income statements of VIE | Armata Pharmaceuticals, Inc. Balance Sheet Information ​
​ | ​ | ​ | ​
​ |  | September 30,
(In thousands) | ​ | 2020
Current assets | ​ | $ | 17,024
Noncurrent assets | ​ | $ | 28,651
Current liabilities | ​ | $ | 7,070
Noncurrent liabilities | ​ | $ | 13,986
​ Income Statement Information ​
​ | ​ | ​ | ​
​ |  | For the nine months
​ | ​ | ended September 30,
(In thousands) | ​ | 2020
Revenue | ​ | $ | 319
Loss from operations | ​ | $ | (15,134)
Net loss | ​ | $ | (15,557)
Entasis |
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS |
Schedule of balance sheets and income statements of VIE | Entasis Therapeutics Holdings Inc ​ Balance Sheet Information ​
​ | ​ | ​ | ​
​ |  | September 30,
(In thousands) | ​ | 2020
Current assets | ​ | $ | 68,398
Noncurrent assets | ​ | $ | 1,564
Current liabilities | ​ | $ | 6,862
Noncurrent liabilities | ​ | $ | 864
​ Income Statement Information ​
​ | ​ | ​ | ​
​ |  | For the six months
​ | ​ | ended September 30,
(In thousands) | ​ | 2020
Loss from operations | ​ | $ | (26,080)
Net loss | ​ | $ | (24,529)

X
- Definition Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -URI http://asc.fasb.org/topic&trid=2196928 + Details
Name: | us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2C -URI http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bb) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 5A -URI http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5747-111685 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=121559654&loc=SL6228884-111685 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685 + Details
Name: | us-gaap_ScheduleOfVariableInterestEntitiesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |